SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Merrimack Pharmaceuticals, Inc. (MACK)

MACK RSS Feed
Add MACK Price Alert      Hide Sticky   Hide Intro
Moderator: $Pistol Pete$
Search This Board: 
Last Post: 4/27/2017 12:50:48 PM - Followers: 64 - Board type: Free - Posts Today: 0



Welcome to Merrimack Pharmaceuticals, Inc. (MACK) Board!!!



At Merrimack, researchers, clinicians, professionals, and, yes, engineers work together in a multidisciplinary, team-based environment. All are committed to a single vision. Building cures for cancer.

 

       Our Leadership

           Robert J. Mulroy has served as our President and Chief Executive Officer and a member of our board of directors since May 1999. Prior to joining us, Mr. Mulroy worked as a management consultant in the pharmaceutical and healthcare                  industries. Mr. Mulroy has also worked as a consultant in the field of international development and has served as an advisor to multiple start-up companies in the biotechnology industry. Mr. Mulroy holds a master’s degree in public and                    private  management from Yale University and a BA from Stanford University.

           Yasir B. Al-Wakeel, BM BCh, has served as our Chief Financial Officer and Head of Corporate Development since August 2015. Dr. Al-Wakeel previously served in various capacities at Credit Suisse, an investment bank, from January 2008            to June 2015. While at Credit Suisse, Dr. Al-Wakeel was most recently a Director of Healthcare Investment Banking focused on biotechnology and, prior to that role, he was an Equity Research Analyst covering the biotechnology and                        specialty pharmaceuticals sectors. Before joining Credit Suisse, Dr. Al-Wakeel was a practicing physician, holding both clinical and academic medical posts. Dr. Al-Wakeel holds a BM BCh (Doctor of Medicine) from Oxford University, an MA            in theology from Cambridge University and a BA from Cambridge University.

           Peter N. Laivins has served as our Head of Development since May 2014. Mr. Laivins served as our Vice President of Clinical Development from October 2011 to May 2014. Previously, Mr. Laivins ran an independent consulting practice                  specializing in oncology and neuroscience from January 2010 to October 2011. Prior to that, Mr. Laivins served as Vice President of Strategic Marketing at Elan Corporation, plc, a biopharmaceutical company, from 2006 to January 2010.                Mr. Laivins began his career at Pfizer Canada, joined Pfizer International in New York in 1995 and held positions of increasing responsibility at Pfizer Inc., culminating as Group Leader of Pfizer US Oncology Marketing until 2006. Mr. Laivins            holds an  MBA and a BS from McGill University.

           Gavin MacBeath, PhD, is a founder of Merrimack and Head of Translational Medicine. Dr. MacBeath leads translational research and drives our innovative diagnostic programs, helping to ensure we get the right drug to the right patient at                the right time. He is also a founder of Chestnut Pharmaceuticals, serves on the Scientific Advisory Board of Aushon Biosciences and is a Lecturer and Principal Investigator at Harvard Medical School. He joined Merrimack in 2009 after                    serving on the  faculty in the Department of Chemistry and Chemical Biology at Harvard University for eight years where he focused on developing and applying protein microarray technology to facilitate basic research in the area of systems            biology. Dr. MacBeath holds a Bachelors of Science from University of Manitoba, Canada, and a PhD in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in La Jolla, California.

           William M. McClements has served as our Head of Corporate Operations since September 2011. Previously, Mr. McClements served as Chief Human Resources Officer of Integreon Managed Solutions, Inc., a global research and business            services company, from May 2010 to September 2011. Prior to that, Mr. McClements served as Chief Operating Officer and a partner at Monitor Group, a global strategic advisory firm, where he worked from 1987 to May 2010. From                        September 2009 to March 2010, Mr. McClements also served as Acting President of Be the Change, Inc., a nonprofit focused on creating national issue-based campaigns. Mr. McClements holds an MBA from Harvard Business School and              a BA from Williams College.

           Birgit M. Schoeberl, PhD, has served as our Head of Discovery since January 2015. Dr. Schoeberl served as our Senior Vice President of Research from January 2014 to January 2015, as our Vice President of Research from October 2009            to January 2014 and in various other research roles since she joined us in 2003. Prior to joining us, Dr. Schoeberl was a post-doctoral fellow at the Massachusetts Institute of Technology, where she built some of the earliest computational                models of  signaling networks. Dr. Schoeberl holds a PhD in systems biology from the Max Planck Institute for Dynamics of Complex Technical Systems in Germany and an MS in chemical engineering from the University of Karlsruhe in                  Germany.

           Edward J. Stewart has served as our Head of Commercial since December 2011. Mr. Stewart served as our Senior Vice President of Business Development from March 2009 to December 2011 and in various other business development                roles since he joined us in 2001. Mr. Stewart began his career at KPMG Peat Marwick LLP in the life sciences strategy consulting group. Mr. Stewart holds an MBA from the Johnson Graduate School of Management at Cornell University                and a BS from  Bates College.

          William A. Sullivan has served as our Head of Finance and Accounting since August 2015 and our Treasurer since February 2010. Mr. Sullivan served as our Chief Financial Officer from May 2011 to August 2015, as our Vice President of               Finance from February 2010 to May 2011, and as our Controller from November 2007 to February 2010. Previously, Mr. Sullivan served as Corporate Controller of Vette Corp., a thermal management solutions company, from 2004 to 2007.             Mr. Sullivan began his career at Arthur Andersen LLP, where he obtained his certified public accountant license. Mr. Sullivan holds an MBA and an MS in accounting from Northeastern University’s Graduate School of Professional                             Accounting and a BA from Williams College.
 

     Contact Us

        One Kendall Square
        Building 700, Suite B7201
        Cambridge, MA 02139
        Phone: 617-441-1000
 




 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MACK
Current Price
Volume:
Bid Ask Day's Range
SureTrader
MACK News: Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research 04/17/2017 07:00:00 AM
MACK News: Initial Statement of Beneficial Ownership (3) 04/10/2017 03:44:27 PM
MACK News: Initial Statement of Beneficial Ownership (3) 04/10/2017 03:38:42 PM
MACK News: Current Report Filing (8-k) 04/07/2017 04:25:48 PM
MACK News: Amended Statement of Ownership (sc 13g/a) 04/07/2017 03:24:02 PM
PostSubject
#601  Sticky Note $MACK Merrimack Declares $140M Special Dividend in Connection $Pistol Pete$ 04/13/17 10:54:58 AM
#634   Nice move higher in Mack this week. Rock_nj 04/27/17 12:50:48 PM
#633   Strong close $Pistol Pete$ 04/25/17 08:31:25 PM
#632   Higher base forming for May dividend run. Rock_nj 04/24/17 05:50:34 PM
#631   The stock does not automatically drop $1.06. Wreckingballer 04/21/17 12:49:45 AM
#630   I am slightly amazed $MACK isn't over $4 roger wilco 04/19/17 02:28:19 PM
#629   $4 is very possible imo. Approx 33% dividend EM 04/19/17 02:02:13 PM
#628   $MACK I can't wait to see this break $Pistol Pete$ 04/19/17 12:16:23 PM
#627   $MACK up up and away !!!!! On my roger wilco 04/19/17 12:15:56 PM
#626   $MACK 15' Chart http://stockcharts.com/c-sc/s $Pistol Pete$ 04/19/17 11:25:55 AM
#625   My group is loading and holding on this $Pistol Pete$ 04/17/17 04:09:53 PM
#624   The chart looks fantastic.. how many confirmed bottoms adtime 04/17/17 04:08:17 PM
#623   $MACK chart is bullish now and did you $Pistol Pete$ 04/17/17 04:02:36 PM
#622   Starting to not see the point for shareholders adtime 04/17/17 02:39:51 PM
#621   For sure I will hold them long on $Pistol Pete$ 04/17/17 02:31:32 PM
#620   You may want to think about holding longer adtime 04/17/17 02:22:51 PM
#619   The record date determines which SHARES receive the dividend. adtime 04/17/17 02:21:30 PM
#618   May 18th right? Since you need to be adtime 04/17/17 02:09:55 PM
#617   My bet it is May 30 for the $Pistol Pete$ 04/16/17 07:02:59 PM
#616   $MACK currently $3.11 a share, that's a whopper roger wilco 04/16/17 06:51:17 PM
#615   I thought May 30 is the special divi.. adtime 04/16/17 06:46:59 PM
#614   nive $MACK mick 04/13/17 05:26:29 PM
#613   $MACK 15' Chart http://stockcharts.com/c-sc/s $Pistol Pete$ 04/13/17 01:37:49 PM
#612   24 million shares short to cover to avoid Rock_nj 04/13/17 01:36:29 PM
#611   Welcome to the party $Pistol Pete$ 04/13/17 12:19:11 PM
#610   Smart move. I have added as well EM 04/13/17 12:15:57 PM
#609   Yep and I am loading and holding until $Pistol Pete$ 04/13/17 12:05:21 PM
#608   Solid base for $mack at $3. With Rock_nj 04/13/17 12:03:28 PM
#607   Yes for sure $Pistol Pete$ 04/13/17 11:40:33 AM
#606   $MACK short term $4.84 and could break 52 $Pistol Pete$ 04/13/17 11:35:23 AM
#605   one i own maybe do da same ????? mick 04/13/17 11:20:42 AM
#604   do ya think buyout or $MACK PROTECTED THE mick 04/13/17 11:16:41 AM
#603   very good read peter/ outstanding divy mick 04/13/17 11:15:59 AM
#602   $MACK Daily and Weekly Chart http://stockchar $Pistol Pete$ 04/13/17 11:15:06 AM
#601   $MACK Merrimack Declares $140M Special Dividend in Connection $Pistol Pete$ 04/13/17 10:54:58 AM
#600   Seeking Alpha on $MACK roger wilco 04/12/17 04:38:35 PM
#599   Thanks..learn something new every day...I have my dividend esad1 04/06/17 08:43:59 AM
#598   OK....I just read it..Makes no sense but it esad1 04/06/17 08:41:58 AM
#597   Special cash dividends make up a large percentage meikodog 04/06/17 07:21:25 AM
#596   It is actually correct. Read up on Rock_nj 04/06/17 06:43:38 AM
#595   Ex dividend date is wrong..How can it go esad1 04/06/17 06:40:56 AM
#594   Dividend declared after the bell today. Special Rock_nj 04/06/17 12:25:38 AM
#593   No...they sold the shares short and have to esad1 04/03/17 06:28:14 PM
#592   Will they pay the dividend to those they Rock_nj 04/03/17 02:07:57 PM
#591   Yes and we should hear this week about esad1 04/03/17 01:42:02 PM
#590   Sounds like the deal just closed and MACK Rock_nj 04/03/17 12:56:35 PM
#589   With a $3.00 stock a $1.00 dividend is esad1 03/31/17 08:25:26 AM
#588   Yes, MACK is in good financial shape to Rock_nj 03/31/17 07:06:02 AM
#587   It was not a dividend deal per se...it esad1 03/31/17 06:13:17 AM
#586   Mack dividend deal approved. Rock_nj 03/30/17 02:48:13 PM
#585   Tomorrow is showtime. Stock has been oddly Rock_nj 03/29/17 09:52:12 PM
PostSubject